Skip to main content
TNXP
NASDAQ Life Sciences

Tonix Pharma Details Positive TNX-4800 Lyme Disease Data, Outlines Phase 2 Study

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$13.84
Mkt Cap
$224.606M
52W Low
$11.603
52W High
$69.97
52W Position info
19% above low
Off High info
80% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

TNXP sits 19% above its 52-week low of $11.603.

Summary

Tonix Pharmaceuticals released detailed positive Phase 1 data for its Lyme disease candidate TNX-4800, supporting a long-acting regimen and outlining plans for a Phase 2 study in 2027.


Key Events · Product Development and Regulatory · TNXP

  • Detailed Phase 1 Pharmacokinetic Data

    Simulations from the Phase 1 trial of TNX-4800 predict that a two-dose regimen can maintain protective serum levels (above 10 µg/mL) for up to six months, supporting its potential as a long-acting prophylactic for Lyme disease.

  • Planned Adaptive Phase 2 Study

    The company plans to initiate an adaptive Phase 2 field study for TNX-4800 in the first half of 2027, pending agreement from the U.S. Food and Drug Administration.

  • FDA Meeting Scheduled

    A Type C meeting with the FDA is scheduled for early Q3 2026 to discuss the planned Phase 2 study design for TNX-4800.

  • Favorable Safety Profile Confirmed

    The Phase 1 study confirmed TNX-4800 was safe and well-tolerated, with dose-proportional pharmacokinetics and a mean half-life of 62-69 days.


Analysis · TNXP · Life Sciences

This 8-K provides detailed pharmacokinetic data from the Phase 1 trial of TNX-4800, a prophylactic for Lyme disease, demonstrating its potential for long-acting protection. The company also outlined plans for an adaptive Phase 2 field study in 1H 2027, including a scheduled FDA meeting. This progress in a key pipeline asset is crucial for Tonix, which has recently reported significant losses and a 'going concern' warning, offering a potential path to future revenue.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNXP was trading at $13.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $224.6M. The 52-week trading range was $11.60 to $69.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNXP - Latest Insights

TNXP
Nov 13, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $3.07 info
Change: +$0.0792 (+3%) info
Market Cap: $58.489M info
TNXP
Nov 09, 2026, 8:25 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $3.07 info
Change: -$0.9308 (-23%) info
Market Cap: $58.489M info
TNXP
Nov 09, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $3.07 info
Change: -$1.03 (-25%) info
Market Cap: $58.489M info
TNXP
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $3.07 info
Change: -$1.28 (-29%) info
Market Cap: $58.489M info
TNXP
Oct 27, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.36
Real-time Price: $3.07 info
Change: -$2.29 (-43%) info
Market Cap: $58.489M info